Browse APOC1

Summary
SymbolAPOC1
Nameapolipoprotein C-I
Aliases Apo-CI; ApoC-I; apo-CIB; apoC-IB; apolipoprotein C-I variant I; apolipoprotein C-I variant II; apolipoprotei ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted
Domain PF04691 Apolipoprotein C-I (ApoC-1)
Function

Inhibitor of lipoprotein binding to the low density lipoprotein (LDL) receptor, LDL receptor-related protein, and very low density lipoprotein (VLDL) receptor. Associates with high density lipoproteins (HDL) and the triacylglycerol-rich lipoproteins in the plasma and makes up about 10% of the protein of the VLDL and 2% of that of HDL. Appears to interfere directly with fatty acid uptake and is also the major plasma inhibitor of cholesteryl ester transfer protein (CETP). Binds free fatty acids and reduces their intracellular esterification. Modulates the interaction of APOE with beta-migrating VLDL and inhibits binding of beta-VLDL to the LDL receptor-related protein.

> Gene Ontology
 
Biological Process GO:0006066 alcohol metabolic process
GO:0006631 fatty acid metabolic process
GO:0006633 fatty acid biosynthetic process
GO:0006638 neutral lipid metabolic process
GO:0006639 acylglycerol metabolic process
GO:0006641 triglyceride metabolic process
GO:0006869 lipid transport
GO:0006898 receptor-mediated endocytosis
GO:0008202 steroid metabolic process
GO:0008203 cholesterol metabolic process
GO:0009894 regulation of catabolic process
GO:0009895 negative regulation of catabolic process
GO:0010565 regulation of cellular ketone metabolic process
GO:0010872 regulation of cholesterol esterification
GO:0010873 positive regulation of cholesterol esterification
GO:0010876 lipid localization
GO:0010899 regulation of phosphatidylcholine catabolic process
GO:0010900 negative regulation of phosphatidylcholine catabolic process
GO:0010915 regulation of very-low-density lipoprotein particle clearance
GO:0010916 negative regulation of very-low-density lipoprotein particle clearance
GO:0010984 regulation of lipoprotein particle clearance
GO:0010985 negative regulation of lipoprotein particle clearance
GO:0015748 organophosphate ester transport
GO:0015850 organic hydroxy compound transport
GO:0015914 phospholipid transport
GO:0015918 sterol transport
GO:0016042 lipid catabolic process
GO:0016053 organic acid biosynthetic process
GO:0016125 sterol metabolic process
GO:0019216 regulation of lipid metabolic process
GO:0019217 regulation of fatty acid metabolic process
GO:0019218 regulation of steroid metabolic process
GO:0030100 regulation of endocytosis
GO:0030258 lipid modification
GO:0030301 cholesterol transport
GO:0032368 regulation of lipid transport
GO:0032369 negative regulation of lipid transport
GO:0032371 regulation of sterol transport
GO:0032372 negative regulation of sterol transport
GO:0032374 regulation of cholesterol transport
GO:0032375 negative regulation of cholesterol transport
GO:0033344 cholesterol efflux
GO:0033700 phospholipid efflux
GO:0034367 macromolecular complex remodeling
GO:0034368 protein-lipid complex remodeling
GO:0034369 plasma lipoprotein particle remodeling
GO:0034375 high-density lipoprotein particle remodeling
GO:0034377 plasma lipoprotein particle assembly
GO:0034379 very-low-density lipoprotein particle assembly
GO:0034381 plasma lipoprotein particle clearance
GO:0034382 chylomicron remnant clearance
GO:0034433 steroid esterification
GO:0034434 sterol esterification
GO:0034435 cholesterol esterification
GO:0034447 very-low-density lipoprotein particle clearance
GO:0034638 phosphatidylcholine catabolic process
GO:0042157 lipoprotein metabolic process
GO:0042180 cellular ketone metabolic process
GO:0042304 regulation of fatty acid biosynthetic process
GO:0044283 small molecule biosynthetic process
GO:0045717 negative regulation of fatty acid biosynthetic process
GO:0045806 negative regulation of endocytosis
GO:0045833 negative regulation of lipid metabolic process
GO:0045834 positive regulation of lipid metabolic process
GO:0045922 negative regulation of fatty acid metabolic process
GO:0045940 positive regulation of steroid metabolic process
GO:0046394 carboxylic acid biosynthetic process
GO:0046470 phosphatidylcholine metabolic process
GO:0046486 glycerolipid metabolic process
GO:0046890 regulation of lipid biosynthetic process
GO:0048259 regulation of receptor-mediated endocytosis
GO:0048261 negative regulation of receptor-mediated endocytosis
GO:0050994 regulation of lipid catabolic process
GO:0050995 negative regulation of lipid catabolic process
GO:0051004 regulation of lipoprotein lipase activity
GO:0051005 negative regulation of lipoprotein lipase activity
GO:0051051 negative regulation of transport
GO:0051055 negative regulation of lipid biosynthetic process
GO:0051346 negative regulation of hydrolase activity
GO:0060191 regulation of lipase activity
GO:0060192 negative regulation of lipase activity
GO:0060627 regulation of vesicle-mediated transport
GO:0065005 protein-lipid complex assembly
GO:0071825 protein-lipid complex subunit organization
GO:0071827 plasma lipoprotein particle organization
GO:0071830 triglyceride-rich lipoprotein particle clearance
GO:0072330 monocarboxylic acid biosynthetic process
GO:0097006 regulation of plasma lipoprotein particle levels
GO:0097164 ammonium ion metabolic process
GO:1901615 organic hydroxy compound metabolic process
GO:1902652 secondary alcohol metabolic process
Molecular Function GO:0004857 enzyme inhibitor activity
GO:0004859 phospholipase inhibitor activity
GO:0005504 fatty acid binding
GO:0008047 enzyme activator activity
GO:0031210 phosphatidylcholine binding
GO:0031406 carboxylic acid binding
GO:0033293 monocarboxylic acid binding
GO:0043168 anion binding
GO:0055102 lipase inhibitor activity
GO:0060228 phosphatidylcholine-sterol O-acyltransferase activator activity
GO:0070405 ammonium ion binding
Cellular Component GO:0032994 protein-lipid complex
GO:0034358 plasma lipoprotein particle
GO:0034361 very-low-density lipoprotein particle
GO:0034364 high-density lipoprotein particle
GO:0034385 triglyceride-rich lipoprotein particle
GO:0042627 chylomicron
GO:1990777 lipoprotein particle
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-73923: Lipid digestion, mobilization, and transport
R-HSA-174824: Lipoprotein metabolism
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-8866423: VLDL biosynthesis
R-HSA-8855121: VLDL interactions
Summary
SymbolAPOC1
Nameapolipoprotein C-I
Aliases Apo-CI; ApoC-I; apo-CIB; apoC-IB; apolipoprotein C-I variant I; apolipoprotein C-I variant II; apolipoprotei ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between APOC1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolAPOC1
Nameapolipoprotein C-I
Aliases Apo-CI; ApoC-I; apo-CIB; apoC-IB; apolipoprotein C-I variant I; apolipoprotein C-I variant II; apolipoprotei ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of APOC1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolAPOC1
Nameapolipoprotein C-I
Aliases Apo-CI; ApoC-I; apo-CIB; apoC-IB; apolipoprotein C-I variant I; apolipoprotein C-I variant II; apolipoprotei ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of APOC1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.530.436
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.8090.838
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3150.919
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1110.872
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.7990.524
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.2670.434
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.3360.62
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.4820.807
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2980.898
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5310.871
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4130.937
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1850.342
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of APOC1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolAPOC1
Nameapolipoprotein C-I
Aliases Apo-CI; ApoC-I; apo-CIB; apoC-IB; apolipoprotein C-I variant I; apolipoprotein C-I variant II; apolipoprotei ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of APOC1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolAPOC1
Nameapolipoprotein C-I
Aliases Apo-CI; ApoC-I; apo-CIB; apoC-IB; apolipoprotein C-I variant I; apolipoprotein C-I variant II; apolipoprotei ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of APOC1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by APOC1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolAPOC1
Nameapolipoprotein C-I
Aliases Apo-CI; ApoC-I; apo-CIB; apoC-IB; apolipoprotein C-I variant I; apolipoprotein C-I variant II; apolipoprotei ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of APOC1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolAPOC1
Nameapolipoprotein C-I
Aliases Apo-CI; ApoC-I; apo-CIB; apoC-IB; apolipoprotein C-I variant I; apolipoprotein C-I variant II; apolipoprotei ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of APOC1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolAPOC1
Nameapolipoprotein C-I
Aliases Apo-CI; ApoC-I; apo-CIB; apoC-IB; apolipoprotein C-I variant I; apolipoprotein C-I variant II; apolipoprotei ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between APOC1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolAPOC1
Nameapolipoprotein C-I
Aliases Apo-CI; ApoC-I; apo-CIB; apoC-IB; apolipoprotein C-I variant I; apolipoprotein C-I variant II; apolipoprotei ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting APOC1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.